\n<\/p>\n
Type 2 diabetes is a health condition involving a problem with the way the human body regulates and uses sugar\/glucose as fuel. New research from Iran found CBD\/THC may be helpful in regulating sugar levels. <\/p>\n
Type 2 diabetes differs from type 1 diabetes in that the latter is a genetic condition that is typically detected early in life, whereas the former is considered to be a lifestyle-related condition that develops over time.<\/p>\n
As of 2020, it was\u00a0estimated\u00a0that over \u2018462 million individuals are affected by type 2 diabetes, corresponding to 6.28% of the world\u2019s population.\u2019 Common treatments and strategies for combating type 2 diabetes include eating healthier, exercising, losing weight, insulin therapy, and blood sugar monitoring.<\/p>\n
Researchers in Iran recently conducted a study involving a sublingual spray containing CBD and THC to see if it helped patients diagnosed with type 2 diabetes. Below is more information about the study via a news release from\u00a0NORML:<\/p>\n
Tehran, Iran:\u00a0<\/strong>Diabetic patients administered a sublingual spray containing CBD and THC show improvements in their blood sugar and cholesterol levels, according to\u00a0placebo-controlled data\u00a0published in the\u00a0Iranian Journal of Pharmaceutical Research<\/em>.<\/p>\n A team of Iranian investigators evaluated the efficacy of a proprietary formulation of plant-derived CBD\/THC compared to placebo in a cohort of 50 patients with type 2 diabetes. Patients utilized the spray twice daily for eight weeks. The sublingual formulation contained a ten-to-one ratio of CBD to THC.<\/p>\n Compared to placebo, cannabinoid therapy was associated with a \u201cstatistically significant decline in total cholesterol, triglycerides, LDL-C, FBS [fasting blood glucose levels], Hb [hemoglobin] A1C, and insulin secretion \u2026 at the end of the 8-week treatment period. \u2026 [T]here were no statistically significant differences in reported adverse effects between the two groups.\u201d<\/p>\n Researchers concluded: \u201cIn the present study, we demonstrated that sublingual administration of [a CBD\/THC] spray, \u2026 twice daily through an eight-week treatment period could effectively improve the patient\u2019s lipid profile and glucose tolerance. \u2026\u00a0Based on these observations, the combination of CBD\/\u03949-THC regimen could be a new therapeutic regimen for controlling the lipid profile and glycemic state of DM [type 2 diabetic] patients.\u201d<\/p>\n Clinical trial data has previously\u00a0shown\u00a0that the administration of the cannabinoid THCV (tetrahydrocannabivarin) decreases fasting glucose levels in type 2 diabetics.<\/p>\n Population-based studies have\u00a0reported\u00a0that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control. Observational studies have also\u00a0shown\u00a0that the\u00a0past use of cannabis is significantly associated with\u00a0lower odds\u00a0of diabetes in adults.<\/p>\n Full text of the study, \u201cA phase I randomized, placebo-controlled study on efficacy and safety profile of a sublingually administered cannabidiol\/delta-9-tetrahydrocannabinol (10: 1) regimen in diabetes Type 2 patients,\u201d appears in the Iranian Journal of Pharmaceutical Research<\/em>.\u00a0Additional information on\u00a0<\/em>cannabinoids and diabetes<\/em>\u00a0is available from NORML\u2019s publication<\/em>,\u00a0Clinical Applications for Cannabis and Cannabinoids<\/em>.<\/p>\n